- Home
- GIGM vs PSTV Comparison
GIGM vs PSTV Comparison
Compare GIGM & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- PSTV
- Stock Information
- Founded
- GIGM 1998
- PSTV 1996
- Country
- GIGM Taiwan
- PSTV United States
- Employees
- GIGM N/A
- PSTV N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- PSTV Medical/Dental Instruments
- Sector
- GIGM Technology
- PSTV Health Care
- Exchange
- GIGM Nasdaq
- PSTV Nasdaq
- Market Cap
- GIGM 20.2M
- PSTV 17.0M
- IPO Year
- GIGM 2000
- PSTV N/A
- Fundamental
- Price
- GIGM $1.64
- PSTV $0.83
- Analyst Decision
- GIGM
- PSTV Strong Buy
- Analyst Count
- GIGM 0
- PSTV 4
- Target Price
- GIGM N/A
- PSTV $8.00
- AVG Volume (30 Days)
- GIGM 21.7K
- PSTV 43.3M
- Earning Date
- GIGM 10-29-2025
- PSTV 11-13-2025
- Dividend Yield
- GIGM N/A
- PSTV N/A
- EPS Growth
- GIGM N/A
- PSTV N/A
- EPS
- GIGM N/A
- PSTV N/A
- Revenue
- GIGM $3,250,000.00
- PSTV $5,317,000.00
- Revenue This Year
- GIGM N/A
- PSTV $28.09
- Revenue Next Year
- GIGM N/A
- PSTV N/A
- P/E Ratio
- GIGM N/A
- PSTV N/A
- Revenue Growth
- GIGM N/A
- PSTV N/A
- 52 Week Low
- GIGM $1.33
- PSTV $0.16
- 52 Week High
- GIGM $1.89
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- GIGM 45.38
- PSTV 66.33
- Support Level
- GIGM $1.57
- PSTV $0.59
- Resistance Level
- GIGM $1.72
- PSTV $0.94
- Average True Range (ATR)
- GIGM 0.07
- PSTV 0.08
- MACD
- GIGM -0.03
- PSTV 0.04
- Stochastic Oscillator
- GIGM 24.01
- PSTV 79.95
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).